Title: Enzalutamide in metastatic prostate cancer before chemotherapy
Authors: Beer, Tomasz M ×
Armstrong, Andrew J
Rathkopf, Dana E
Loriot, Yohann
Sternberg, Cora N
Higano, Celestia S
Iversen, Peter
Bhattacharya, Suman
Carles, Joan
Chowdhury, Simon
Davis, Ian D
de Bono, Johann S
Evans, Christopher P
Fizazi, Karim
Joshua, Anthony M
Kim, Choung-Soo
Kimura, Go
Mainwaring, Paul
Mansbach, Harry
Miller, Kurt
Noonberg, Sarah B
Perabo, Frank
Phung, De
Saad, Fred
Scher, Howard I
Taplin, Mary-Ellen
Venner, Peter M
Tombal, Bertrand
PREVAIL Investigators
Van Poppel, Hendrik #
Issue Date: Jul-2014
Series Title: The New England journal of medicine vol:371 issue:5 pages:424-33
Article number: 10.1056/NEJMoa1405095
Abstract: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.
ISSN: 0028-4793
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science